Advertisement
AQST vs HROW
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a Hold and HROW is a Buy.
AQST sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for AQST moved above the 200-day moving average on September 18, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AQST's RSI Indicator exited the oversold zone, 31 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where AQST advanced for three days, in 213 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AQST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AQST as a result. In 70 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for AQST turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
AQST moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AQST crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for AQST entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.050) is normal, around the industry mean (11.138). P/E Ratio (-6.182) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (10.730) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. AQST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
HROW's RSI Oscillator ascending out of oversold territory
The RSI Indicator for HROW moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 34 of the 41 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for HROW just turned positive on October 20, 2026. Looking at past instances where HROW's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
Following a +2.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in 240 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
HROW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for HROW entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HROW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. HROW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (69.648) is normal, around the industry mean (11.138). P/E Ratio (-28.525) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
AQST | HROW | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 84 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 67 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 62 | 81 | |
P/E GROWTH RATING 1..100 | 44 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AQST's Valuation (11) in the Pharmaceuticals Major industry is significantly better than the same rating for HROW (84) in the Pharmaceuticals Other industry. This means that AQST’s stock grew significantly faster than HROW’s over the last 12 months.
HROW's Profit vs Risk Rating (67) in the Pharmaceuticals Other industry is somewhat better than the same rating for AQST (100) in the Pharmaceuticals Major industry. This means that HROW’s stock grew somewhat faster than AQST’s over the last 12 months.
HROW's SMR Rating (99) in the Pharmaceuticals Other industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that HROW’s stock grew similarly to AQST’s over the last 12 months.
AQST's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as HROW (81) in the Pharmaceuticals Other industry. This means that AQST’s stock grew similarly to HROW’s over the last 12 months.
HROW's P/E Growth Rating (14) in the Pharmaceuticals Other industry is in the same range as AQST (44) in the Pharmaceuticals Major industry. This means that HROW’s stock grew similarly to AQST’s over the last 12 months.
| AQST | HROW | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 82% | N/A |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 83% |
| Advances ODDS (%) | 2 days ago 84% | 2 days ago 82% |
| Declines ODDS (%) | 7 days ago 84% | 9 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 75% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AQST’s FA Score shows that 1 FA rating(s) are green while HROW’s FA Score has 1 green FA rating(s).
- AQST’s FA Score: 1 green, 4 red.
- HROW’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AQST’s TA Score shows that 5 TA indicator(s) are bullish while HROW’s TA Score has 5 bullish TA indicator(s).
- AQST’s TA Score: 5 bullish, 6 bearish.
- HROW’s TA Score: 5 bullish, 2 bearish.
Price Growth
AQST (@Pharmaceuticals: Generic) experienced а -11.50% price change this week, while HROW (@Pharmaceuticals: Generic) price change was +3.67% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
AQST is expected to report earnings on Nov 04, 2026.
HROW is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
AQST and
Correlation & Price change
A.I.dvisor indicates that over the last year, AQST has been loosely correlated with HROW. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if AQST jumps, then HROW could also see price increases.
| Ticker / NAME | Correlation To AQST | 1D Price Change % | ||
|---|---|---|---|---|
| AQST | 100% | +0.74% | ||
| HROW - AQST | 35% Loosely correlated | +0.61% | ||
| SXTC - AQST | 35% Loosely correlated | +11.79% | ||
| ACET - AQST | 26% Poorly correlated | -0.66% | ||
| CPHI - AQST | 26% Poorly correlated | -3.78% | ||
| SNDL - AQST | 24% Poorly correlated | N/A | ||
More | ||||
HROW and
Correlation & Price change
A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AQST. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AQST could also see price increases.
| Ticker / NAME | Correlation To HROW | 1D Price Change % | ||
|---|---|---|---|---|
| HROW | 100% | +0.61% | ||
| AQST - HROW | 35% Loosely correlated | +0.74% | ||
| AMRX - HROW | 30% Poorly correlated | +1.81% | ||
| AYTU - HROW | 28% Poorly correlated | -2.49% | ||
| RMTI - HROW | 27% Poorly correlated | -2.07% | ||
| TEVA - HROW | 27% Poorly correlated | -0.56% | ||
More | ||||